technology successful you applications XXX, our commitment off quarter quarter have customers second and across close. a thank joining for our end XXXX I'd for continued morning, with broad our thanking markets. we our by start and diverse and team like serving At second a call. Thanks, to Kelly. for to platform Good to bringing dedication earnings their
current is are applications, pharmaceuticals, macro emergence life devastating the our a research reflected was devices the of advantage, serving environment, critical X.X. of the in products science ascent We portfolio as and growing including handheld counterfeit diversity financial the of of key biopharma and including market desktop serving applications, our Our particularly end and omics market our in this Bioprocess and results. multi view rise forensics
revenue again, million. devices, quarter recurring which increased continued Once base bringing X,XXX globally. we second Our represented year-over-year placed XX% to in to saw We more the law that our devices analysis. one-third our need revenue, strength enforcement, growth XXX period or year over X% than prior installed be of they revenue. point value and in in research total military, growth customers, comprised the This whether our demonstrates biopharma institutions, of $XX.X
by really I'm Overall, encouraged these results.
and chemical detection, more We continue internationally. increasingly to U.S. the both opportunities for handheld in capture
X.X control advanced need there As process take to with to Bioprocess begins hold modalities critical monitor analytics demonstrative robust and therapeutics, is parameters. of for a
these a We are take opportunities. advantage developing solid foundation to building of
clear. large the technology need abundantly with proteomics targeted launched or and for in other Society instruments At June, the was ASMS mass American vendors faster applications. for significantly frame spec Mass Conference for Spectrometry Key speeds omics processing
chips Our speed to prototype warp well microfluidic are meet for this need suited processing.
I'll have majority key at share presentation on highlights with collaborators with had record ASMS year omics. a in and this a the multi XX We call. oral later this presence posters,
update first our to Starting XXXX. across key objective, for penetrate we have radiate our provide accounts. on focus brief areas across Now I'd like made a with the and three progress
Nearly noting accounts seven more May, second with year the preliminary of to to across is the drug enterprise to fentanyl. overdose. data CDC attributed were overdoses foothold drive focus released and XXX,XXX like that Americans radiate In a these dying was to Our out XXXX XX penetrate then new synthetic broader accounts from create than adoption. opioids consecutive
where Biden in with plan of of to fentanyl the the and detected released disrupting was includes coming deaths. involved being Xylazine report CDC supply. the laced July, is problem combat fentanyl recent determining in the X-point Another Xylazine administration XX% And found from a that Xylazine. nearly That
MXXXX illicit our their Customs Xylazine other and handheld fentanyl many narcotics of its detection from analogs, use trace entering provides device agencies borders. chemical to drugs. and device Our prevent illegal
U.S. and in with with the Security Border a how metropolitan Geographic work our the and of our was major Department airport. agents them the Smuggler training at highlighted their Customs to channel. episode Agency the showed the Protection Homeland Catch investigations on use specialists series MXXXX The application to one June, support of In National a on
customers day every country We are our the from that the communities. employees counterfeit into of our our of stem flow proud work entering in and do helping drugs our
XXX use MXXXX our which law pilot Ohio, enforcement device. program I now in XX noted been successful in have Previously, officers in counties the have to trained
As central reduction notable the in has state a backlogs. evidence a lab result, seen
program's this we I'm replicate speed to agencies is of and goal program excited in Tennessee success and law taskforces other several pilot have drug identification enforcement drug with states, begun process. state's Our efficiency a to the and enhance the that
devices Tennessee of for law introduce process. across MXXXX drug will agencies judicial with illicit to to the lab sent the pilot of central initial eight of which the lessen will primary also the with This the in enforcement quantity an samples program testing, objective decreasing seed delays
in leading In the decisions improved public MXXXX This more outcomes. to is safer playbook we agencies can and device using same enforcement now informed success faster with at the law of Ohio. need, health communities used point addition, make the ultimately and
control. between of partnership. pharma potential developed came monitoring our our that key desktops, is Also key each of renewed of use. and foster to with existing revenue long-standing to we are to Further, the former pleased for Analytics, a our OEM our account, list routine XX% online agreement XX three This the workflows note, relationship in this OEM focused providing of and are approximately strategy desktop including drive pharmaceutical we've Sartorius, we Sartorius from customers them sampler customers, companies. top Trace on maximize to and bioreactor the support a and top with and customers Turning sensors
introduced the need. are and and connected we and understanding point leverages while toxic that broadening objective, adds answers Beacon monitoring portfolio, process In MXXXX and first is solution develop public Beacon improved and second safety to our focus, module gather of advancing simple large our ensuring devices and of a focus use our line core in MXXXX customers device cloud-based responders order infrastructure. our Turning air remote remotely with and robust continuously with enables continuous hazards. vapor week, this to product events aero at last for to provide for and intelligence key to that the at at to aerosol
installed The other up can which MXXXX widespread The smartphone, systems laptop, in area time MXXXX large used for aerosol coverage. with through monitored to through device. capability, offer one the and portal, continuously or X,XXX detect mobile With hazards. additional of field, remotely integrated only be seamlessly systems the accessed this over vapor real or which Beacon easily beacons and devices we set have can in Beacon can is the and that identify be MXXXX and base a can individually any be
organizations For Institute Training, that continue on in One partner biopharmaceutical that with National Ireland. advance technologies alliance and NIBRT, innovative formed is Bioprocessing key our we developing based the focused desktops, with an of organization we Research to manufacturing. or have such
to cell is manufacturing proteins, For research of the gene focus and that therapies. past recombinant and XX transformative revolutionize make vaccines, NIBRT's years, discoveries the
for platform profiling, fluid, multi-characterization in spectrometer method cell use that and At Smith Josh a offers applications Jonathan amino peptide proteins ready culture of Bones go impact ASMS, noted breakfast seminar versatile device native the such mass new of for workflow. ZipChip a well-attended from we that acid a highlighted ZipChip NIBRT. our box. of as held charge a that's out to featured Bones analysis these different the to Dr. and He mapping of coupled applications doctors
for lack of for traditional serotypes adeno-associated highlighted gene analysis virus, compared presentations or the posters which ASMS. method Smith the were are short speakers ZipChip's results of Dr. therapy high rapid successful AAV, of highlighted times the use of also in at development. to critical Both LC/MS, The of manufacturing. these and three sensitivity, various touted analysis ZipChip
our and and making sample requiring cancer. characterize published The product ZipChip bioprocessing for technology monoclonal tool reliable of the recent NIBRT In colorectal for addition, the and a used to device in CEMS Analysis, highly treatment authors scientists Journal a intact in Lonza that analysis from enables article thus Pharmaceutical in powerful minimal fast Biologics pipeline. a while sensitive of early noted preparation, Biomedical it characterization our antibody mass
Engineering gain and continue After in momentum bioprocessing. April. In and growing recombinant forum, biologics, convene backgrounds the experts viral to advancements gene and We exposure impact discuss regulatory, to through and and industrial nearly a from finally that including to Culture was in-person spectrum poster cell leaders modalities, the culture and and held therapies, vaccines. speaking due Conference cell of related academic, this focused conferences the opportunities Cell marketing presentations invitation-only absence on COVID-XX pandemic, five-year at
to analyzer. We to with research Three poster from participate culture and of the presented gained insights key with and along using invited our learnings conference application presentation, leaders. valuable opportunity opinion a each scientists network cell our the were REBEL on
in in Lastly, street launch device suite further of our will up month of that exciting desktop our process addition devices. our next the from at is for our key and new this International monitoring our just Bioprocess an believe includes and team preparing device products Boston, is MAVEN bioprocess of the REBEL headquarters. the transform Conference the parameters it We to
oral mass see spec-based a we omics showing this clear strong third technical to workflows address institutions at with had posters, our metabolomics majority as to one This proteomics turning conference, XX research partners. academic accelerating and foundation, presentation emerging opportunities. and year's industry with the finally, well ASMS And was an a for objective, evident and collaborators need we as where from lay and
microfluidic on an from world its at dried from Dr. unifying and multi-omics principal single XX allowed Thompson, containing workflow top-down Thompson capillary peptidomic, our Mark chips bottom-up sample Will scientist ZipChip described Duke University on electrophoresis. Dr. microchip prototype gave proteomics collaboration blood. independent presentation microliters of device, with Professor using oral the the with our Devices, metabolomic, Foster in which XXX a
ZipChip University was and Cell collaborators, and of need sample faster want our omics and spec can our Regenerative of to the Ling instruments meet Professor workflows. Biology with Scientists for chips, significantly was conducting mass our a theme device, this We Ge, research believe poster at This sets prototype by are of Wisconsin-Madison. of Chemistry and at large Speed tools process a definitive demanding other exemplified multi proteomics, for along and speed. one metabolomics ASMS. number
and human poster heart A ease so provide with use. specifically that of times. noted Ge's separation significant is metabolomics of multi highlighted ZipChip long separation has LCMS a proteomics minutes, device's She omics traditional the extract. speed and analysis, Professor in top-down protein bottom-up advantage, along can
as well of growing enthusiastic support for also on this provided R&D key leaders multi Scientific and we ASMS, R&D-related content our Proteomic hosted as our conference meeting of opinion at At feedback a where omics. Board, Advisory presence emerging in efforts customer
of Our peptide the of members approach the particularly were multi under unified in scientific large peptides developmental board omics including pre-concentration advisory biofluids. for analysis on-chip analysis interested very studies capability ZipChip using conditions, native from for
remarkable in forward to this their we are this on to exciting an made thought product stated We launch group we area. Overall, next the the pleased fortunate leaders our efforts objectives, month. advance with insights and second progress have as development during really quarter look share our of I'm I
With call our now Joe on financials. for more turn I'll that, details to over the
